0.755

0.99% 0.0074

After Hours: .75 -0.005 -0.66%

Revelation Biosciences Inc (REVB)

Overview News Price History Financials Discussions Forecast Stock Split

Revelation Biosciences Inc stock is traded at $0.755, with a volume of 130.57K. It is up +0.99% in the last 24 hours and down -9.53% over the past month. Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Previous Close:

$0.7476

Open:

$0.7476

24h Volume:

130.57K

Relative Volume:

0.26

Market Cap:

$3.21M

Revenue:

Net Income/Loss:

$-120.30K

P/E Ratio:

-1.3725

EPS:

-0.5501

Net Cash Flow:

$-7.29M

1W Performance:

-0.50%

1M Performance:

-9.53%

6M Performance:

-58.74%

1Y Performance:

-96.16%

1-Day Range:

$0.7423

$0.76

1-Week Range:

$0.7321

$0.7936

52-Week Range:

$0.702

$25.26

Revelation Biosciences Inc Stock (REVB) Company Profile

Name

Revelation Biosciences Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

650-800-3717

Address

4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

REVB's Discussions on Twitter

Compare REVB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REVB Revelation Biosciences Inc	0.755	3.21M	0	-120.30K	-7.29M	-0.5501
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Revelation Biosciences Inc Stock (REVB) Latest News

Nov 20, 2024

Warning: REVB is at high risk of performing badly - MSN

Nov 20, 2024

Nov 12, 2024

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - BioSpace

Nov 12, 2024

Revelation Bio Achieves Key Manufacturing Milestone for Kidney Disease Drug Trial | REVB Stock News - StockTitan

Nov 12, 2024

Nov 11, 2024

United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com

Nov 11, 2024

Allergic Rhinitis Treatment Market Size in the 7MM is expected to Grow by 2034 | DelveInsight - Barchart

Nov 11, 2024

REVB: Good Expense Control as Company Prepares for Trials - Research Tree

Nov 11, 2024

Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews

Nov 11, 2024

Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket - Benzinga

Nov 11, 2024

REVB Results Set Stage for Future Growth - Yahoo Finance

Nov 11, 2024

Nov 08, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - sharewise

Nov 08, 2024

Revelation Biosciences Inc expected to post a loss of $2.29 a shareEarnings Preview - XM

Nov 08, 2024

Revelation Bio Q3 Loss Narrows to $2.2M, Secures $3.8M from Warrants Amid Cash Decline | REVB Stock News - StockTitan

Nov 08, 2024